Activity and Safety of Ruxolitinib-Based Combination Therapies for Patients with Myelodysplastic Syndromes/Myeloproliferative Neoplasms


Activity and Safety of Ruxolitinib-Based Combination Therapies for Patients with Myelodysplastic Syndromes/Myeloproliferative Neoplasms
Slides from presentations at ASH 2015 and transcribed comments from a recent interview with Richard M Stone, MD (2/16/16)

Daver N et al. 5-azacytidine (AZA) in combination with ruxolitinib (RUX) as therapy for patients (pts) with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs). Proc ASH 2015;Abstract 823.

Gupta V et al. Phase 1b/2 study of the efficacy and safety of sonidegib (LDE225) in combination with ruxolitinib (INC424) in patients with myelofibrosis. Proc ASH 2015;Abstract 825.

Stegelmann F et al. A Phase-Ib/II study of ruxolitinib plus pomalidomide in myelofibrosis. Proc ASH 2015;Abstract 826.

Durrant ST et al. An open-label, multicenter, 2-arm, dose-finding, Phase 1b study of the combination of ruxolitinib and buparlisib (BKM120) in patients with myelofibrosis: Results from HARMONY study. Proc ASH 2015;Abstract 827.

Dr Stone is Director of the Adult Leukemia Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts.